Samantha Semenkow
Stock Analyst at Citi
(3.53)
# 2,243
Out of 4,676 analysts
210
Total ratings
51.6%
Success rate
4.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Samantha Semenkow
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARGX argenx SE | Maintained: Buy | $1,203 → $1,301 | $1,019.49 | +27.61% | 21 | Aug 18, 2026 | |
| NKTR Nektar Therapeutics | Maintained: Buy | $151 | $74.96 | +101.44% | 11 | Aug 14, 2026 | |
| ROIV Roivant Sciences | Maintained: Buy | $42 → $46 | $36.47 | +26.13% | 6 | Aug 10, 2026 | |
| GPCR Structure Therapeutics | Maintained: Buy | $97 | $49.92 | +94.31% | 7 | Aug 10, 2026 | |
| CGEM Cullinan Therapeutics | Maintained: Buy | $33 | $22.95 | +43.79% | 3 | Aug 6, 2026 | |
| BIOA BioAge Labs | Maintained: Buy | $52 → $21 | $10.11 | +107.72% | 11 | Aug 6, 2026 | |
| RYTM Rhythm Pharmaceuticals | Maintained: Buy | $142 → $143 | $113.35 | +26.16% | 3 | Aug 5, 2026 | |
| AGIO Agios Pharmaceuticals | Maintained: Buy | $46 → $52 | $33.90 | +53.39% | 5 | Jul 31, 2026 | |
| WVE Wave Life Sciences | Maintained: Buy | $24 → $19 | $5.25 | +261.90% | 5 | Jul 31, 2026 | |
| LRMR Larimar Therapeutics | Maintained: Buy | $14 | $4.16 | +236.54% | 19 | Jun 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $57 → $61 | $43.50 | +40.23% | 16 | Jun 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $11 | $3.81 | +188.71% | 2 | Jun 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $68 | $31.03 | +119.14% | 15 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $64 → $97 | $107.36 | -9.65% | 3 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $4 | $2.17 | +84.33% | 6 | Apr 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $14 → $17 | $14.38 | +18.22% | 6 | Apr 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $11 | $3.48 | +216.09% | 6 | Mar 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | $6 | $15.56 | -61.44% | 9 | Mar 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 | $4.10 | +192.68% | 14 | Mar 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $5 → $4.25 | $3.71 | +14.56% | 8 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $3.22 | +210.56% | 11 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $15 → $5 | $3.28 | n/a | 9 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $6 → $4 | $34.52 | n/a | 8 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $1.7 → $0.75 | $0.0001 | n/a | 3 | May 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $130 | $26.17 | n/a | 1 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $16 → $7 | $3.78 | n/a | 2 | Jul 21, 2021 |
argenx SE
Aug 18, 2026
Maintained: Buy
Price Target: $1,203 → $1,301
Current: $1,019.49
Upside: +27.61%
Nektar Therapeutics
Aug 14, 2026
Maintained: Buy
Price Target: $151
Current: $74.96
Upside: +101.44%
Roivant Sciences
Aug 10, 2026
Maintained: Buy
Price Target: $42 → $46
Current: $36.47
Upside: +26.13%
Structure Therapeutics
Aug 10, 2026
Maintained: Buy
Price Target: $97
Current: $49.92
Upside: +94.31%
Cullinan Therapeutics
Aug 6, 2026
Maintained: Buy
Price Target: $33
Current: $22.95
Upside: +43.79%
BioAge Labs
Aug 6, 2026
Maintained: Buy
Price Target: $52 → $21
Current: $10.11
Upside: +107.72%
Rhythm Pharmaceuticals
Aug 5, 2026
Maintained: Buy
Price Target: $142 → $143
Current: $113.35
Upside: +26.16%
Agios Pharmaceuticals
Jul 31, 2026
Maintained: Buy
Price Target: $46 → $52
Current: $33.90
Upside: +53.39%
Wave Life Sciences
Jul 31, 2026
Maintained: Buy
Price Target: $24 → $19
Current: $5.25
Upside: +261.90%
Larimar Therapeutics
Jun 30, 2026
Maintained: Buy
Price Target: $14
Current: $4.16
Upside: +236.54%
Jun 30, 2026
Maintained: Buy
Price Target: $57 → $61
Current: $43.50
Upside: +40.23%
Jun 15, 2026
Reiterated: Buy
Price Target: $11
Current: $3.81
Upside: +188.71%
May 13, 2026
Maintained: Buy
Price Target: $68
Current: $31.03
Upside: +119.14%
May 6, 2026
Rated: Buy
Price Target: $64 → $97
Current: $107.36
Upside: -9.65%
Apr 9, 2026
Rated: Buy
Price Target: $4
Current: $2.17
Upside: +84.33%
Apr 2, 2026
Maintained: Buy
Price Target: $14 → $17
Current: $14.38
Upside: +18.22%
Mar 23, 2026
Reiterated: Buy
Price Target: $11
Current: $3.48
Upside: +216.09%
Mar 20, 2026
Maintained: Sell
Price Target: $6
Current: $15.56
Upside: -61.44%
Mar 4, 2026
Maintained: Buy
Price Target: $12
Current: $4.10
Upside: +192.68%
Nov 11, 2025
Maintained: Hold
Price Target: $5 → $4.25
Current: $3.71
Upside: +14.56%
Oct 10, 2025
Reiterated: Buy
Price Target: $10
Current: $3.22
Upside: +210.56%
Mar 6, 2025
Maintained: Buy
Price Target: $15 → $5
Current: $3.28
Upside: n/a
Jun 3, 2024
Initiated Coverage: Buy
Price Target: $6 → $4
Current: $34.52
Upside: n/a
May 18, 2023
Maintained: Hold
Price Target: $1.7 → $0.75
Current: $0.0001
Upside: n/a
May 11, 2023
Rated: Buy
Price Target: $130
Current: $26.17
Upside: n/a
Jul 21, 2021
Maintained: Buy
Price Target: $16 → $7
Current: $3.78
Upside: n/a